| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e46477872db4077bfdc5e9cb2f3d4492 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-744
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-747
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-46 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-747
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-744 |
| filingDate |
2015-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d20ad549b04f0d1a11ccdc2e57b59e3 |
| publicationDate |
2017-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017112883-A1 |
| titleOfInvention |
A composition for use in treating or preventing viral or bacterial infections in a subject undergoing anti-tumor chemotherapy, leukemia treatment or aids therapy comprising l. reuteri ler03 and/or l. salivarius ls06 |
| abstract |
A composition for use as adjunctive therapy to antitumor chemotherapeutic treatments, acquired immunodeficiency syndrome treatments and leukemia treatments is described. The composition includes a strain of bacteria Lactobacillus reuteri LRE 03 DSM 23879 which is able to strongly stimulate the production of pro-inflammatory cytokines (Th1) interferon INF-gamma, the cytokines exhibiting a marked antiviral and/or antibacterial activity, and/or a bacterial strain Lactobacillus salivarius LS06 DSM 26037 which is able to strongly stimulate dendritic cell production, the dendritic cells exhibiting a marked antiviral and/or antibacterial activity. The composition can include one or more of: a bacterial strain able to produce, when ingested, bacterial exopolysaccharides EPS; and/or a plant polysaccharide such as tara gum; and/or an Aloe arborescens gel; and/or a gelling agent such as sodium alginate and/or a highly bioavailable zinc internalized into a tyndallized bacterial cell. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10413576-B2 |
| priorityDate |
2014-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |